A. Menarini Diagnostics and Nucleix Form Strategic Partnership for Non-Invasive Bladder Cancer Test in Europe
A. Menarini Diagnostics and Nucleix have announced a strategic commercial agreement to exclusively market the Bladder EpiCheck® test in Europe. This non-invasive, CE-marked urine test is designed to detect and monitor bladder...
Read More